Varices, Esophageal Recruiting Phase 4 Trials for Octreotide (DB00104)

Also known as: Oesophageal Varices / Esophageal Varices / Varices oesophageal / Esophageal varices without bleeding / Varices esophageal / Esophageal varices (disorder) / Oesophageal varices NOS / Esophageal varices with bleeding / Oesophageal varices haemorrhage / Oesophageal varices ruptured / Esophageal varices ruptured / Oesophageal varices with bleeding / Bleeding oesophageal varices / Esophageal varices hemorrhage / Bleeding esophageal varices / Bleeding esophageal varices (disorder)

IndicationStatusPhase
DBCOND0046998 (Varices, Esophageal)Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03624517Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal VaricesTreatment